Correction of toxic impact of anti-tuberculosis drugs on the liver in patients with first-time diagnosis of pulmonary tuberculosis
DOI:
https://doi.org/10.11603/mcch.2410-681X.2017.v0.i3.8191Keywords:
active lung tuberculosis, toxic liver damage, hepatoprotector Antral.Abstract
Introduction. The liver, being the main organ of detoxification, is experiencing the greatest burden in the process of chemotherapy. Disorders of the liver function in patients with respiratory tuberculosis can occur due to various factors, leading to the development of toxic reactions up to acute and chronic hepatitis. Numerous studies point to pronounced hepatotoxic effect of all anti-TB drugs and development of toxic hepatitis in patients treated with these drugs. This suggests the need to use hepatotropic drugs in complex treatment of TB.
The aim of the study – to learn biochemical markers of liver function abnormalities in patients with newly diagnosed pulmonary tuberculosis and with severe intoxication syndrome before and two months after TB inpatient treatment, and the feasibility of using domestically-produced “Antral“ medication to treat functional disorders of the liver in these patients.
Research methods. Two groups of people were involved in the study. Group I (control) consisted of evidently healthy donors, 27 individuals; Group II (31 individuals) consisted of patients with newly diagnosed pulmonary tuberculosis and with severe intoxication syndrome before and two months after of anti-TB therapy. This group was randomly divided into two subgroups: IIA(15 individuals), patients that only received standard anti-TB treatment and IIB (16 individuals), patients along with the standard anti-TB therapy received “Antral“ medication in the dose of 200 mg 3 times a day for the duration of treatment intensive phase.
Results and Discussion. Results of the study indicate that when examining patients with pulmonary tuberculosis and severe intoxication syndrome markers of cytolysis and cholestasis should be measured prior to start of the treatment. With the increase of such indicators, in particular, ALT, AST, general and direct bilirubin, LDH, GGTP should be appointed hepatoprotector, in particular "Antral" drug. The use of this drug during the intensive phase of treatment normalizes the parameters of not only cytolytic but also cholestatic syndromes of liver function disorders in patients. Use of this medication in the treatment of tuberculosis contributed to ceasing release of the bacteria after intensive phase of treatment in 71.2 % of cases in subgroup IIB (43.9 % in subgroup IIA), and disappearance of clinical manifestations of intoxication in subgroup IIB in 79.8 % of cases (49.6 % in subgroup IIA). Significant reduction in markers of cytolysis and cholestasis was observed in patients that received “Antral“ medication during intensive phase of the treatment.
Conclusions. Patients with newly-detected pulmonary tuberculosis and severe intoxication syndrome had significantly increased markers of cytolysis and cholestasis even before start of the treatment. “Antral“ is a medication with hepatoprotective action. Use of this medication alongside with the complex therapy of pulmonary tuberculosis contributed to normalization of liver function, significant reduction in the markers of cytolysis and cholestasis, faster termination of bacterial release and disappearance of clinical manifestations of intoxication.
References
Sukhanov, D.S. (2012). Effektivnost gepatoprotektornogo deystviya i otsenka riskov pri ispolzovanii reamberina, remaksola i ademetionina u bolnykh tuberkulezom organov dykhaniya s lekarstvennymi porazheniyami pecheni [Efficacy of hepatoprotective action and risk assessment using reamberin, remaxol and ademethionine in patients with respiratory tuberculosis with medicinal liver lesions]. Terapevticheskiy arkhiv – Therapeutic Archive, 84 (11), 26-29 [in Russian].
Ivanova, D.A., & Tityukhina, M.V. (2014). Lekarstvennyye porazheniya pecheni pri lechenii bolnykh tuberkulezom [Drug-induced liver injury during treatment of tb patients]. Tuberkuloz i sotsialno znachimyye zabolevaniya – Tuberculosis and Socially Significant Diseases, (1-2), 32-43 [in Russian].
Balasanyants, G.S., & Sukhanov, D.S. (2011). Pobochnyye deystviya protivotuberkuleznykh preparatov i metody ikh ustraneniya [Side effects of anti-TB drugs and methods for their elimination]. Saint-Petersburg: Taktik-Studio [in Russian].
Volf, S.B., Sukhanov, D.S., & Romantsov, M.G. (2009). Medikamentoznyye porazheniya pecheni pri polikhimioterapii tuberkuleza [Medicamentous lesions of the liver with polychemotherapy of tuberculosis]. Vestnik Sankt-Peterburgskoy gosudarstvennoy meditsinskoy akademii im. I.I. Mechnikova – Journal of Saint-Petersburg State Medical Academy by I.I. Mechnikov, (1), 172-176 [in Russian].
Tsapyak, T.A., Shakhbazidi, G., Klyaritskaya, I.L., & Shibayeva N.A. (2010). Lekarstvennoye porazheniye pecheni pri polikhimioterapii aktivnogo tuberkuleza [Drug failure of liver in chemotherapy of tuberculosis disease]. Krymskyi terapevtychnyi zhurnal – Crimean Therapeutic Journal, 1, 46-49 [in Russian].
Samohalska, O.Ye., Babiak, O.V. (2011). Analiz efektyvnosti antraliu pry likuvanni alkoholnoho tsyrozu pechinky [Analysis of the effectiveness of anthral in the treatment of alcoholic cirrhosis of the liver]. Suchasna hastroenterolohiia – Modern Gastroenterology, 4 (60), 135-139 [in Ukrainian].
Hryshchuk, L.A., Bilyk, S.O., & Hryshchuk, O.L. (2008). Likuvannia suputnoi patolohii pechinky u khvorykh na tuberkuloz lehen iz vykorystanniam preparatu Enerliv [Treatment of concomitant liver disease in patients with pulmonary tuberculosis using the preparation Enerliv]. Vnutrishnia medytsyna – Internal Medicine, 5 (11), 69-71 [in Ukrainian].
Novikova, T.I., & Novikov, V.S. (2011). Opyt primeneniya preparata «Fosfogliv» v terapii porazheniya pecheni na fone khimioterapii legkikh [Experience with the use of "Phosphogliv" in the treatment of liver damage on the background of lung chemotherapy]. Tuberkulez i bolezni legkikh – Tuberculosis and diseases of lungs, 5 (88), 76 [in Russian].
Voznenko, A.A., Aksonova, V.A., & Odinets, V.S. (2011). Korrektsiya narusheniy funktsii pecheni u bolnykh tuberkulozom organov dykhaniya [Correction of liver function disorders in patients with respiratory tuberculosis]. Meditsinskiy vestnik severnogo Kavkaza – Medical Journal of North Caucasus, 4, 38-41 [in Russian].
Hussain, T., Gupta, R.K., Khan, К.S., Hussain, M., Arif M., Hussain A., … Rao C.V. (2012). Evaluation of antihepatotoxic potential of Solanumxanthocarpum fruit extract against antitubercular drugs induced hepatopathy in experimental rodents. Asian Pac. J. Trop. Biomed., 2 (6), 454-460. doi: 10.1016/S2221-1691(12)60075-6.
Unifikovanyi klinichnyi protokol pervynnoi, vtorynnoi (spetsializovanoi) ta tretynnoi (vysokospetsializovanoi) medychnoi dopomohy doroslym. Tuberkuloz [Nakaz MOZ Ukrainy vid 04.09.2014 r. № 620]. Kyiv: Ministerstvo okhorony zdorovia, 2014 [in Ukrainian].
Antralʹ®, instruktsiia, zastosuvannia preparatu ANTRAL. Retrieved from: ANTRALʹ®, instruktsiia, zastosuvannia preparatu ANTRALʹ® Tabletky, vkryti obolonkoiu, po 0.1 h, 0.2 h №10, №10kh3 u konturnykh charunkovykh upakovkakh.
